TuHURA Biosciences (NASDAQ:HURA) Stock Price Up 1.7% – Still a Buy?

TuHURA Biosciences (NASDAQ:HURA)’s share price traded up 1.7% during mid-day trading on Thursday . The company traded as high as $3.72 and last traded at $3.62. 114,112 shares traded hands during trading, a decline of 59% from the average session volume of 276,926 shares. The stock had previously closed at $3.56.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company. HC Wainwright initiated coverage on shares of TuHURA Biosciences in a research note on Monday, March 3rd. They issued a “buy” rating and a $13.00 price target for the company. Finally, RODMAN&RENSHAW upgraded shares of TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th.

TuHURA Biosciences Stock Up 1.7 %

The firm has a 50 day moving average of $3.58.

Hedge Funds Weigh In On TuHURA Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Jefferies Financial Group Inc. purchased a new position in TuHURA Biosciences in the fourth quarter valued at about $54,000. Squarepoint Ops LLC purchased a new position in shares of TuHURA Biosciences in the fourth quarter worth about $223,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of TuHURA Biosciences during the 4th quarter valued at approximately $128,000. Millennium Management LLC bought a new position in shares of TuHURA Biosciences in the fourth quarter worth $138,000. Finally, Bank of America Corp DE purchased a new stake in shares of TuHURA Biosciences in the fourth quarter worth about $59,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.